SCHEMBL652764

SCHEMBL652764

CCCCn1c(-c2ccccc2C)nc(Cl)c1CN(Cc1ccc(OC)cc1)Cc1ccc2[nH]ncc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 2/20 0.38
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35
ROCK2 O75116 6/20 0.35
ROCK1 Q13464 5/20 0.35
CCR2 P41597 3/20 0.35
SMPD1 P17405 1/20 0.35
GSK3A P49840 1/20 0.34
GSK3B P49841 1/20 0.34
PRKG1 Q13976 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34
MAOB P27338 2/20 0.34
S1PR1 P21453 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
ALDH1A1 P00352 2/20 0.33
RXFP1 Q9HBX9 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
QPCT Q16769 1/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650190 0.94 ROCK2 (0.38) TRPA1ROCK2ROCK1MAOBMAPT
SCHEMBL648229 0.87 TRPA1 (0.39) TRPA1ROCK2ROCK1S1PR1MEN1
SCHEMBL650605 0.86 TRPA1 (0.38) TRPA1ROCK2ROCK1GSK3AGSK3B
SCHEMBL5181418 0.83 SMPD1 (0.40) DRD2DRD3SMPD1ALDH1A1RXFP1
SCHEMBL648120 0.80 SMPD1 (0.38) DRD2DRD3SMPD1MEN1KMT2A
SCHEMBL652703 0.80 ROCK2 (0.35) TRPA1ROCK2ROCK1GSK3AGSK3B
SCHEMBL648737 0.80 TSHR (0.37) ALDH1A1RXFP1L3MBTL1TSHR
SCHEMBL5181407 0.79 SMPD1 (0.41) SMPD1ALDH1A1RXFP1L3MBTL1TP53
SCHEMBL650987 0.78 CALM1 (0.41) MAPT
SCHEMBL5181414 0.77 CRHR1 (0.36) SMPD1MEN1KMT2AALDH1A1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed